Cite
Biodistribution and Dosimetry of Intraventricularly Administered 124 I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.
MLA
Pandit-Taskar, Neeta, et al. “Biodistribution and Dosimetry of Intraventricularly Administered 124 I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 60, no. 12, Dec. 2019, pp. 1794–801. EBSCOhost, https://doi.org/10.2967/jnumed.118.219576.
APA
Pandit-Taskar, N., Zanzonico, P. B., Kramer, K., Grkovski, M., Fung, E. K., Shi, W., Zhang, Z., Lyashchenko, S. K., Fung, A. M., Pentlow, K. S., Carrasquillo, J. A., Lewis, J. S., Larson, S. M., Cheung, N.-K. V., & Humm, J. L. (2019). Biodistribution and Dosimetry of Intraventricularly Administered 124 I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 60(12), 1794–1801. https://doi.org/10.2967/jnumed.118.219576
Chicago
Pandit-Taskar, Neeta, Pat B Zanzonico, Kim Kramer, Milan Grkovski, Edward K Fung, Weiji Shi, Zhigang Zhang, et al. 2019. “Biodistribution and Dosimetry of Intraventricularly Administered 124 I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 60 (12): 1794–1801. doi:10.2967/jnumed.118.219576.